A persistently low CD4/CD8 ratio has been reported to inversely correlate with the risk of non-AIDS defining cancer in people living with human immunodeficiency virus (HIV; PLWH) efficiently treated by combination antiretroviral therapy (cART). We evaluated the impact of the CD4/CD8 ratio on the risk of Kaposi sarcoma (KS) or non-Hodgkin lymphoma (NHL), still among the most frequent cancers in treated PLWH.
CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies / Caby, Fabienne; Guiguet, Marguerite; Weiss, Laurence; Winston, Alan; Miro, Jose M; Konopnicki, Deborah; Le Moing, Vincent; Bonnet, Fabrice; Reiss, Peter; Mussini, Cristina; Poizot-Martin, Isabelle; Taylor, Ninon; Skoutelis, Athanasios; Meyer, Laurence; Goujard, Cécile; Bartmeyer, Barbara; Boesecke, Christoph; Antinori, Andrea; Quiros-Roldan, Eugenia; Wittkop, Linda; Frederiksen, Casper; Castagna, Antonella; Thurnheer, Maria Christine; Svedhem, Veronica; Jose, Sophie; Costagliola, Dominique; Mary-Krause, Murielle; Grabar, Sophie. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - 73:1(2021), pp. 50-59. [10.1093/cid/ciaa1137]
CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies
Mussini, Cristina;
2021
Abstract
A persistently low CD4/CD8 ratio has been reported to inversely correlate with the risk of non-AIDS defining cancer in people living with human immunodeficiency virus (HIV; PLWH) efficiently treated by combination antiretroviral therapy (cART). We evaluated the impact of the CD4/CD8 ratio on the risk of Kaposi sarcoma (KS) or non-Hodgkin lymphoma (NHL), still among the most frequent cancers in treated PLWH.Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris